NICM
CRSP icon

Neo Ivy Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Neo Ivy Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.1K Sell
1,725
-77,001
-98% -$4.06M 0.02% 287
2025
Q4 		$4.13M Buy
+78,726
New +$4.71M 0.65% 50

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Neo Ivy Capital Management's CRSP Position: Q1 2026 in Review

Neo Ivy Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 98% in Q1 2026, selling an estimated $4.06M and leaving 1,725 shares worth $82.1K. The position accounts for 0.02% of the portfolio, ranked #287.

Neo Ivy Capital Management first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.13M in Q4 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Neo Ivy Capital Management held 1,725 shares of CRISPR Therapeutics worth $82.1K as of Q1 2026.
  • Neo Ivy Capital Management sold 77,001 CRISPR Therapeutics shares in Q1 2026, an estimated $4.06M.
  • CRISPR Therapeutics made up 0.02% of Neo Ivy Capital Management's portfolio in Q1 2026, its #287 holding.
  • Neo Ivy Capital Management first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Neo Ivy Capital Management's CRISPR Therapeutics position peaked at $4.13M in Q4 2025.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.